Jubilant Pharmova is an API manufacturer based in India. It holds 4 active US drug master files across a filed portfolio of 6 molecules. Its filings concentrate with MINSA (CR) and NCELS (KZ). Its GMP standing is certified by CDSCO (India). Customs aggregates show $39.0M of exports covering 448 molecules to 46 destinations in 2025.
| Site | FDA FEI |
|---|---|
| Mysuru, India | Not on file |
| Molecule | Regulators | Docs |
|---|---|---|
| Olanzapine | SFDA (Saudi Arabia), US FDA | 2 |
| Dalfampridine | US FDA | 1 |
| Donepezil | SFDA (Saudi Arabia) | 1 |
| Lansoprazole | US FDA | 1 |
| Meclizine | US FDA | 1 |
| Sitagliptin | SFDA (Saudi Arabia) | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| MINSA (CR) | 4 | None |
| NCELS (KZ) | 1 | None |
| CDSCO (India) | None | 2 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $120K | 1 |
| 2025 | Not reported | $39.0M | 46 |
| 2024 | Not reported | $41.8M | 45 |
| 2023 | Not reported | $62.2M | 46 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Choose your molecules and target markets. Jubilant Pharmova comes back tiered against every other supplier able to file there.
Start for free